Epilepsia · 2000 · 80 citations · 31 references
MedicineNeurologyOphthalmologyElectrophysiologyVisual ElectrophysiologyVisual NeuroscienceElectrooculogram AnalysisVisual Evoked PotentialsVisual Field AssessmentVisual Field DefectsVisual FunctionVisual NeurophysiologyConstricted Visual FieldElectroretinographyMultifocal ElectroretinogramMultifocal Visual Evoked PotentialsOscillatory PotentialsPattern Visual Evoked PotentialsVigabatrin TherapyVisually Evoked Potentials
PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported. The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously. Six of the patients were no longer receiving vigabatrin. METHODS: The central and peripheral fields were examined with the Humphrey Visual Field Analyzer. Full visual electrophysiology, including flash electroretinography (ERG), pattern electroretinography, multifocal ERG using the VERIS system, electro-oculography, and flash and pattern visual evoked potentials, was undertaken. RESULTS: Seven patients showed marked visual field constriction with some sparing of the temporal visual field. The eighth exhibited concentric constriction. Most electrophysiological responses were usually just within normal limits; two patients had subnormal Arden electro-oculography indices; and one patient showed an abnormally delayed photopic b wave. However, five patients showed delayed 30-Hz flicker b waves, and seven patients showed delayed oscillatory potentials. Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level. CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy. The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.
31
Severe persistent visual field constriction associated with vigabatrin: FIG 1
Tom Eke, J F Talbot, Mark Lawden · BMJ · 1997 · 451 citations
Medicine, Neurology, Neuroscience +17
Vigabatrin-associated retinal cone system dysfunction
Gregory L. Krauss, Mary A. Johnson, Neil R. Miller · Neurology · 1998 · 249 citations
Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects
Reetta Kälviäinen, Iiris Nousiainen, Maija Mäntyjärvi et al. · Neurology · 1999 · 200 citations
Medicine, Neurology, Ophthalmology +16
Visual field defects associated with vigabatrin therapy
Mark Lawden, Tom Eke, Christopher Degg et al. · Journal of Neurology Neurosurgery & Psychiatry · 1999 · 185 citations · Full text
Medicine, Neurology, Ophthalmology +17